U.S. markets open in 5 hours 7 minutes
  • S&P Futures

    3,850.75
    +5.75 (+0.15%)
     
  • Dow Futures

    31,105.00
    +9.00 (+0.03%)
     
  • Nasdaq Futures

    13,354.50
    +60.25 (+0.45%)
     
  • Russell 2000 Futures

    2,157.10
    -0.60 (-0.03%)
     
  • Crude Oil

    52.93
    -0.38 (-0.71%)
     
  • Gold

    1,870.40
    +3.90 (+0.21%)
     
  • Silver

    25.98
    +0.21 (+0.83%)
     
  • EUR/USD

    1.2139
    +0.0024 (+0.19%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.43
    -1.81 (-7.79%)
     
  • GBP/USD

    1.3742
    +0.0087 (+0.64%)
     
  • USD/JPY

    103.4530
    -0.1170 (-0.11%)
     
  • BTC-USD

    32,903.20
    -598.90 (-1.79%)
     
  • CMC Crypto 200

    652.28
    -48.33 (-6.90%)
     
  • FTSE 100

    6,741.52
    +1.13 (+0.02%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Alzamend Neuro®, Inc. Announces Confidential Submission of Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock

·1 min read

Alzamend Neuro®, Inc. ("Alzamend" or the "Company") today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC"). The public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201229005446/en/

Contacts

Email: Info@Alzamend.com or call: 1-844-722-6333
Company Website: www.Alzamend.com